Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joel Robbins

Internal Medicine Arlington Heights, IL Medical Doctor

NPI 1295888105 CMS profile 13881

800 W Central Rd, Arlington Heights, IL 60005

Open in the dashboard

General payments

$12,488

452 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joel Robbins of Arlington Heights, IL is reported in the CMS Open Payments database as having received $12,488 across 452 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,218 48
2024 General $1,333 64
2023 General $1,359 67
2022 General $1,631 78
2021 General $1,555 86
2020 General $1,214 48
2019 General $3,178 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Robbins
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joel Robbins were reported at $2,218. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joel Robbins Internal Medicine median Middle half National median
2019 $3,178 $159 $48–$570 $163
2020 $1,214 $119 $33–$402 $114
2021 $1,555 $135 $37–$521 $132
2022 $1,631 $141 $42–$496 $149
2023 $1,359 $149 $45–$519 $160
2024 $1,333 $154 $47–$537 $164
2025 $2,218 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,456 26 payments
  2. Medtronic, Inc. $1,308 15 payments
  3. Boston Scientific Corporation $1,094 32 payments
  4. Novartis Pharmaceuticals Corporation $1,032 56 payments
  5. Janssen Pharmaceuticals, Inc $956 45 payments
  6. E.R. Squibb & Sons, L.L.C. $907 52 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $655 47 payments
  8. Amarin Pharma Inc. $450 29 payments
  9. Novo Nordisk Inc $354 15 payments
  10. Biotronik Inc. $351 9 payments
  11. Other $2,926 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,644 438 payments
  2. Travel and Lodging $2,739 12 payments
  3. Education $105 2 payments
Products named General payments · program years 2019–2025
  1. Xience V coronary stent system $1,956 9 payments
  2. SYMPLICITY G3 $1,293 14 payments
  3. XARELTO $956 45 payments
  4. WATCHMAN $773 21 payments
  5. ELIQUIS $583 32 payments
  6. LEQVIO $511 23 payments
  7. JARDIANCE $446 29 payments
  8. ENTRESTO $383 26 payments
  9. Ozempic $329 14 payments
  10. Repatha $321 19 payments
  11. Other $5,279 248 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

7,444

Median for Cardiology: 2,533

Drug cost

$1,179,152

Median for Cardiology: $485,213

Branded share of claims

23.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 457 $499,290
Jardiance Empagliflozin Brand 202 $212,036
Entresto Sacubitril/Valsartan Brand 126 $155,180
Camzyos Mavacamten Brand 12 $101,071
Xarelto Rivaroxaban Brand 60 $52,369
Vascepa Icosapent Ethyl Brand 50 $34,908
Farxiga Dapagliflozin Propanediol Brand 14 $14,090
Rosuvastatin Calcium Generic 1,017 $12,158
Edarbyclor Azilsartan Med/Chlorthalidone Brand 24 $10,815
Edarbi Azilsartan Medoxomil Brand 22 $9,941

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$337,330

Of which drugs: $1,610

Medicare patients

675

Average age 76

Services billed

3,674

322 women, 353 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 51%
Atrial fibrillation 36%
Diabetes 32%
Chronic kidney disease 30%
Heart failure 28%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 73 292 $1,557
Infusion, normal saline solution, 250 cc J7050 Office 103 103 $53

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $120
  • PFIZER INC. $29
$149 457 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $148
$148 202 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $132
$132 12 —
VERQUVO
  • Merck Sharp & Dohme Corporation $71
$71 — —
Repatha
  • Amgen Inc. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

452 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record